Novel direct AMPK activator suppresses non-small cell lung cancer through inhibition of lipid metabolism

Drug resistance is becoming an obstacle in anti-cancer therapies. For target-based therapy of lung cancer, gefitinib, as the first generation of tyrosine kinase inhibitors (TKIs), demonstrated good initial response to the non-small cell lung cancer (NSCLC) patients whom harbors epidermal growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xi, Xie, Chun, Fan, Xing-Xing, Jiang, Ze-Bo, Wong, Vincent Kam-Wai, Xu, Jia-Hui, Yao, Xiao-Jun, Liu, Liang, Leung, Elaine Lai-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707083/
https://www.ncbi.nlm.nih.gov/pubmed/29221189
http://dx.doi.org/10.18632/oncotarget.21716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707083/
https://www.ncbi.nlm.nih.gov/pubmed/29221189
http://dx.doi.org/10.18632/oncotarget.21716

Ejemplares similares